Company CVAbout Bafna Pharmaceuticals Ltd 
Bafna Pharmaceuticals Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Company Coordinates
Company Details
Bafna Towers New No 68, Old No 299 Thambu Chetty St Chennai Tamil Nadu : 600001
Registrar Details
Cameo Corporate Services Ltd , Subramanian Buildings No 1 , Club House Road, Chennai
Capital StructureCapital Structure
Present Equity Capital
INR 23.66 Cr
Number of Shares
2.37 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
10-Sep-2020
2.37
23.66
21290701
10
Preferential basis
27-Aug-2019
23.66
2.37
-21290701
10
Reduction - Court Order
12-Feb-2018
2.37
23.66
5000000
10
Conversion of Warrants
17-Jun-2016
1.97
19.66
1000000
10
Allotment of Equity Shares To Promoter & Others
17-Jun-2016
2.27
22.66
3000000
10
Allotment of Equity To Others
17-Jun-2016
1.97
19.66
1000000
10
Allotment of Equity Shares To Promoter & Others
17-Jun-2016
2.27
22.66
3000000
10
Allotment of Equity To Others
15-Sep-2012
1.87
18.66
150000
10
Conversion of Warrants
15-Sep-2012
1.87
18.66
150000
10
Conversion of Warrants
14-Aug-2012
1.85
18.51
125000
10
Conversion of Warrants
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 3 FIIs (9.34%)
Promoter with highest holding
Srjr Lifesciences Llp (74.57%)
Highest Public shareholder
Alpana Mundra (3.25%)
Individual Investors Holdings
12.03%
Board of Directors
Management
Designation
Remuneration
Babulal Kamlesh Kumar
Non-Exec. & Independent Dir.
1.54 lacs
Shanmugam Hemalatha
Chairperson / Executive Direct
14.42 lacs
Akilapriya Chandrashekar Raju
Non-Exec & Non-Independent Dir
0
Palamadai Krishnan Sundaresan
Non-Exec. & Independent Dir.
1.54 lacs
Ravichandran Chitra
Non-Exec. & Independent Dir.
66.0 k
Atul Sachdeva
Non-Exec & Non-Independent Dir
0
Roopa Ravikumar
Company Secretary
0
Vishnu Vasudeva Kuppa
Company Sec. & Compli. Officer
0
Upendar Mekala Reddy
Additional Non Independent Non
0
Krishna Yeachuri
Addtnl Non-Exe Dir &Indpnt Dir
0
Vinayak Dinesh Dendukuri
Whole Time Director (Operatio
0
Upendar Mekala Reddy
Additional Director
0
Krishna Yeachuri
Additional Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals
43.36
100.00%
Pharmaceuticals
Stock DNARevenue and Profits:
Net Sales:
35 Cr
(Quarterly Results - Sep 2025)
Net Profit:
3 Cr
Pharmaceuticals & Biotechnology
INR 353 Cr (Micro Cap)
34.00
27
0.00%
0.29
12.46%
4.25
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
